

September 1, 2016



## OPKO Health to Participate in Upcoming September Conferences

MIAMI--(BUSINESS WIRE)-- **OPKO Health, Inc. (Nasdaq: OPK)**, today announced that senior management will participate in the 11<sup>th</sup> Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9<sup>th</sup> Annual Barrington Research Fall Investment Conference taking place on September 8, 2016 in Chicago.

### **11<sup>th</sup> Annual Wells Fargo Securities Healthcare Conference**

**Date and Time:** September 7, 2016, 11:05 AM EDT

**Website:** [2016 Wells Fargo Healthcare Conference](#)

**Format:** Company presentation

**Presenter:** OPKO Health Senior Management

### **Barrington Research Fall Investment Conference**

**Date:** September 8, 2016

**Website:** [9th Annual Barrington Research Fall Investment Conference](#)

**Format:** One-on-One Meetings

**Presenter:** OPKO Health Senior Management

The 11<sup>th</sup> Annual Wells Fargo Securities Healthcare Conference presentation will be webcast on OPKO Health's Investor Relations page of the corporate website at [www.opko.com](http://www.opko.com). To access the live webcast, please log on to the OPKO site approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

### **About OPKO Health, Inc.**

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the *4Kscore* prostate cancer test and the *Claros 1* in-office immunoassay platform. Our pharmaceutical business features *RAYALDEE*, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and *VARUBI*<sup>™</sup> for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at [www.opko.com](http://www.opko.com).

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20160901006500/en/>

OPKO Health, Inc.

Tara Mackay, 305-575-4100

Investor Relations

or

**Media**

Rooney & Associates

Terry Rooney, 212-223-0689

[trooney@rooneyco.com](mailto:trooney@rooneyco.com)

or

Marion Janic, 212-223-4017

[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)

or

**Investors**

LHA

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

or

Bruce Voss, 310-691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: OPKO Health, Inc.